Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microflora and Pathogens in Women with Urogenital Infections
NCT06616168Phase 1Active, not recruiting
- Sponsor
- Danylo Halytsky Lviv National Medical University
- Start
- Sep 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of Gynoflor in bacterial vaginosis (BV) and Genitourinary Tract Infection (GUTI) (3 arms), sponsored by Danylo Halytsky Lviv National Medical University. Primary endpoints: Estimation of the immune activity at 1 month and Quantities of vaginal microflore bacteria at 2 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
Gynoflor
03
Conditions
bacterial vaginosis (BV)Genitourinary Tract Infection (GUTI)
Beyond the preview
Go deeper on NCT06616168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616168.